Andy Sklawer, Fresh Tracks Therapeutics CEO

Fresh Tracks stops drug pipeline to save mon­ey as it keeps look­ing for an ex­it

Fresh Tracks Ther­a­peu­tics has hit pause on its drug de­vel­op­ment pipeline to save cap­i­tal re­sources and fig­ure out its ex­it strat­e­gy.

The re­search in­ter­rup­tion in­cludes fore­go­ing part two of a Phase I tri­al in­ves­ti­gat­ing its lead as­set FRTX-02 in atopic der­mati­tis. The pause will al­low the Boul­der, CO biotech to plan what’s next for the as­set based on pos­i­tive re­sults re­leased in March from the tri­al’s part-one por­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.